You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

 

1011 Results
Regimen
Cancer Type:
Sarcoma, 
Kaposi's Sarcoma
Intent: Palliative
Funding:
New Drug Funding Program
    Liposomal Doxorubicin - HIV-positive Kaposi's Sarcoma
Mar 2025
Regimen
Cancer Type:
Central Nervous System
Intent: Palliative
Funding:
ODB - General Benefit
    temozolomide
Regimen
Cancer Type:
Central Nervous System
Intent: Adjuvant, Palliative
Funding:
ODB - General Benefit
    temozolomide
Regimen
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Intent: Palliative
Funding:
Exceptional Access Program
    pazopanib - For first-line treatment of advanced or metastatic renal cell carcinoma of clear cell histology in patients with good performance status (ECOG 0-1), with specific criteria
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Palliative
Regimen
Cancer Type:
Lung, 
Small Cell
Intent: Palliative
Nov 2023
Regimen
Cancer Type:
Sarcoma, 
Ewing's
Intent: Neoadjuvant, Adjuvant, Palliative
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Sep 2019
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Palliative
Regimen
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Intent: Palliative
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Regimen
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Intent: Palliative
Funding:
Exceptional Access Program
    SORAfenib - Metastatic renal cell carcinoma of clear cell histology as second-line treatment, with specific criteria
Oct 2020

Pages